Pyle, Melissa
Broome, Matthew R.
Joyce, Emmeline
MacLennan, Graeme
Norrie, John
Freeman, Daniel
Fowler, David
Haddad, Peter M.
Shiers, David
Hollis, Chris
Smith, Jo
Liew, Ashley
Byrne, Rory E.
French, Paul
Peters, Sarah
Hudson, Jemma
Davies, Linda
Emsley, Richard
Yung, Alison
Birchwood, Max
Longden, Eleanor
Morrison, Anthony P.
Funding for this research was provided by:
Health Technology Assessment Programme (15/31/04)
Article History
Received: 17 October 2018
Accepted: 10 June 2019
First Online: 4 July 2019
Ethics approval and consent to participate
: MAPS was approved by the North West - Greater Manchester East REC on 06.02.2017 (reference 16/NW/0893). All participants provided written informed consent to participate in MAPS. For participants under 16 years old, parents/legal guardians also gave written informed consent for the trial team to contact their child before the participant could provide their consent.
: Not applicable.
: We have the following conflict of interests to declare. All authors have conducted funded research into treatments for psychosis. APM has received royalties for CBT manuals and practises CBT in the NHS. DS is expert advisor to the NICE centre for guidelines and a member of the current NICE guideline development group for <i>Rehabilitation in adults with complex psychosis and related severe mental health conditions</i>; Board member of the National Collaborating Centre for Mental Health (NCCMH); views are personal and not those of NICE or NCCMH. PF has received royalties for CBT manuals, is a member of the NIHR HTA Mental Health Prioritisation Panel and Joint National Clinical Advisor to the National Audit of Psychosis. PMH has received fees for lecturing and/or consultancy work from Janssen, Lundbeck, NewBridge Pharmaceuticals, Otsuka and Sunovion plus conference support from Janssen, Lundbeck, NewBridge Pharmaceuticals and Sunovion. JN declares membership of the following NIHR boards: CPR decision making committee; HTA Commissioning Board; HTA Commissioning Sub-Board (EOI); HTA Funding Boards Policy Group; HTA General Board; HTA Post-Board funding teleconference; NIHR CTU Standing Advisory Committee; NIHR HTA & EME (Efficacy and Mechanism Evaluation) Editorial Board; Pre-exposure Prophylaxis Impact Review Panel. JS is Joint National Clinical Advisor to the National Audit of Psychosis and has received fees for lecturing and/or consultancy work from Janssen and Otsuka and book royalties from Wiley-Blackwell publishers. REB has received fees for teaching related to CBTp, and is an invited expert reviewer for the NIHR Health Services and Delivery Programme.